Skip to content
10-Q

Quarterly Report

Oruka Therapeutics, Inc. ORKA

0001213900-25-109182

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 48.41M sh
Capex Q3 2025 · Sep 30, 2025 $146K
Capex Q3 2025 · Sep 30, 2024 $171K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$65.62M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$39.02M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $91.25M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $61.58M
Stockholders Equity Q3 2025 · Sep 30, 2025 $486.79M
Stockholders Equity Q3 2025 · Jun 30, 2025 $343.64M
Stockholders Equity Q3 2025 · Mar 31, 2025 $364.73M
Stockholders Equity Q3 2025 · Dec 31, 2024 $382.22M
Stockholders Equity Q3 2025 · Sep 30, 2024 $342.37M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$28.98M
Stockholders Equity Q3 2025 · Mar 31, 2024 −$7.06M
Stockholders Equity Q3 2025 · Feb 6, 2024 $1K
Current Liabilities Q3 2025 · Sep 30, 2025 $20.97M
Current Liabilities Q3 2025 · Dec 31, 2024 $13.04M
Total Liabilities Q3 2025 · Sep 30, 2025 $22.46M
Total Liabilities Q3 2025 · Dec 31, 2024 $13.8M
Current Assets Q3 2025 · Sep 30, 2025 $355.16M
Current Assets Q3 2025 · Dec 31, 2024 $376.87M
Total Assets Q3 2025 · Sep 30, 2025 $509.25M
Total Assets Q3 2025 · Dec 31, 2024 $396.02M
Rd Expense Q3 2025 · Sep 30, 2025 $28.99M
Rd Expense Q3 2025 · Sep 30, 2025 $73M
Rd Expense Q3 2025 · Sep 30, 2024 $25.69M
Rd Expense Q3 2025 · Sep 30, 2024 $49.56M
Net Income Q3 2025 · Sep 30, 2025 −$30.28M
Net Income Q3 2025 · Sep 30, 2025 −$75.85M
Net Income Q3 2025 · Sep 30, 2024 −$28.62M
Net Income Q3 2025 · Sep 30, 2024 −$57.94M
Operating Income Q3 2025 · Sep 30, 2025 −$34.11M
Operating Income Q3 2025 · Sep 30, 2025 −$87.62M
Operating Income Q3 2025 · Sep 30, 2024 −$29.45M
Operating Income Q3 2025 · Sep 30, 2024 −$57.81M